- Mouse study combining whole-body plethysmography, optogenetics, conditional VGAT knockout, and patch clamp in acute medullary slices examined propofol effects on pre-BötC respiratory rhythm.
- Propofol was compared across doses, and optogenetic activation of pre-BötC GABAergic neurons was tested alone and with propofol; GABAergic neurons were also ablated.
- Propofol produced dose-dependent bidirectional respiratory effects, from mild excitation to marked suppression, with correlated excitatory and inhibitory effects on pre-BötC glutamatergic neurons; no effect sizes are reported in the abstract.
- Authors conclude propofol has a dose-dependent bidirectional effect on respiratory drive via pre-BötC GABAergic neurons; ablation increased apnea incidence during continuous infusion while aiding recovery after a single bolus.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Single-center, double-blind randomized trial of 220 patients undergoing noncardiac surgery, comparing dexmedetomidine with saline placebo.
- Dexmedetomidine 1.5 µg/kg/h IV was started 15 minutes before induction and continued until 15 minutes after induction.
- NOX compliance was 90.7% (98/108) with dexmedetomidine versus 12.5% (14/112) with placebo (P < .001). Postoperative NRS >3 was lower at all time points, e.g., 2.8% vs 25.9% at 0 hours.
- Dexmedetomidine also reduced rescue opioid consumption and postoperative nausea and vomiting, and the authors report improved hemodynamic stability and a favorable safety profile.
- Systematic review and network meta-analysis of 24 randomised trials including 2,130 adults undergoing surgery with single-injection peripheral nerve blocks.
- Compared eight pharmacological prophylactic strategies against control for preventing rebound pain after nerve block.
- Intravenous dexamethasone had the highest probability of reducing rebound pain incidence (SUCRA 0.91) and was judged definitely superior to control.
- Perineural dexamethasone and dexmedetomidine ranked highest for delaying rebound pain, while certainty of evidence ranged from very low to moderate.
- Randomized, blinded, two-center French superiority trial of 320 adults undergoing elective cardiac surgery with cardiopulmonary bypass.
- Patients received opioid-free anesthesia with ketamine, dexamethasone, lidocaine and magnesium, or opioid anesthesia with sufentanil.
- The 30-day composite of complications or death occurred in 75.4% versus 84.5% (RR 0.90; 95% CI 0.80 to 0.99; P = 0.049), with a fragility index of 1.
- The authors call the results hypothesis generating; cardiovascular and digestive complications and deaths were also lower with opioid-free anesthesia.
- This is a pharmacokinetic compartment model, not a clinical study, so no patient sample size is reported.
- The model simulates maternal codeine ingestion across CYP2D6 metabolizer genotypes, including ultra-rapid metabolizers, and transfer of morphine into breastmilk.
- Predicted neonatal morphine concentrations stayed below 1 μg/L regardless of maternal genotype; no confidence intervals or p values are reported.
- The authors conclude that neonatal opioid toxicity from breastfeeding is implausible and that the current ban on codeine for breastfeeding postpartum women should be reviewed.
- Single-center, double-blind, placebo-controlled RCT of 384 women aged 18 to 50 undergoing ambulatory surgery under general anesthesia.
- Participants received oral 5 mg olanzapine or placebo, with both groups also receiving dexamethasone and ondansetron prophylaxis.
- Olanzapine raised QoR-40 scores on POD 1 by 9.0 points (95% CI, 6.1 to 11.8; P < 0.001).
- Olanzapine also lowered the odds of any nausea on POD 1 (OR 0.43) and POD 2 (OR 0.48), while PACU length of stay did not differ.
- Systematic review and meta-analysis of five randomized controlled trials, including 646 adults undergoing brain surgery, with searches run through April 2025.
- Evaluated perioperative dexmedetomidine, given as a loading dose followed by a maintenance infusion, for preventing postoperative delirium.
- The pooled risk ratio was 0.47 (95% CI 0.35-0.63; p < 0.00001), a 53% reduction in delirium risk, with no heterogeneity (I2 = 0%).
- Subgroups showed similar effects across brain tumor and other cranial procedures, adverse events were comparable and mostly mild, and the authors call for multicenter trials.
- Prospective noninferiority RCT of 188 patients with Parkinson's disease randomized 1:1 to undergo elective bilateral deep brain stimulation surgery.
- Desflurane general anesthesia, titrated to electrophysiologic signal quality, was compared with dexmedetomidine conscious sedation.
- High-quality microelectrode recording occurred in 89.4% versus 90.3% (difference -0.96%, 95% CI -9.62 to 7.70), and general anesthesia shortened operative time by 9.07 min (P < 0.001).
- Six-month UPDRS change, levodopa equivalent dose, and complication rates were comparable between groups, and the authors conclude general anesthesia is noninferior.
- Systematic review and meta-analysis of 25 studies including 116,815 surgical patients, with 12 RCTs (n = 845) in the primary analysis.
- Compared perioperative intravenous methadone with other opioids, with respiratory depression defined as naloxone use, respiratory rate under 8/min, or SpO2 under 90%.
- Respiratory depression occurred in 7.7% of methadone patients versus 6.6% of controls, RR 1.22 (95% CI 0.76-1.95), which was not significant.
- The authors found no higher risk with methadone, but rated certainty of evidence as very low, and most data came from retrospective datasets.
- Preclinical study in aged mice using a laparotomy-with-visceral-manipulation model, comparing Sham, POD, and POD+DEX groups with behavioral, hippocampal, and primary microglia analyses.
- Dexmedetomidine treatment was compared against untreated POD mice, with in vitro work using TFEB knockdown in LPS-stimulated primary microglia.
- DEX improved POD-like behaviors and reduced microglial activation and pro-inflammatory cytokines, with increased lysosomal protein expression and TFEB nuclear translocation; no effect sizes or p values are reported in the abstract.
- The authors conclude that TFEB activation may restore microglial lysosomal function and that enhancing lysosomal function could be a potential POD target; DEX also inhibited NLRP3 signaling, which TFEB knockdown substantially attenuated.
- Single-center retrospective cohort of 408 adults undergoing elective cardiovascular surgery (2022–2023), comparing a fixed postoperative dexmedetomidine infusion (n = 188) with no dexmedetomidine (n = 220).
- Exposure was a 24-hour infusion at 0.2 μg/kg/h versus no postoperative dexmedetomidine, with delirium assessed by CAM-ICU at 6 and 24 hours.
- Delirium was less frequent with dexmedetomidine at 6 hours (2.1% vs 7.0%, p = 0.032) and 24 hours (0.5% vs 3.6%, p = 0.042); adjusted OR at 6 hours was 0.25 (95% CI 0.07–0.88).
- Dexmedetomidine was also linked to shorter extubation time (6.85 ± 1.49 vs 9.47 ± 5.61 hours, p < 0.001) and similar adverse events and mortality, though the authors call for prospective confirmation.
- Retrospective, propensity-matched analysis of 61,527 US patients undergoing revision hip or knee arthroplasty for periprosthetic joint infection, 2015 to 2023.
- Compared patients exposed to perioperative dexamethasone with matched unexposed patients in separate nondiabetic (30,644) and diabetic (14,996) cohorts.
- Dexamethasone was associated with fewer aggregate complications in nondiabetic (aOR 0.934, 95% CI 0.760-0.978) and diabetic patients (aOR 0.814, 95% CI 0.746-0.889).
- Only diabetic patients had lower mortality (aOR 0.692, 95% CI 0.532-0.901); the authors conclude dexamethasone appears safe regardless of diabetes status.
- Prospective evaluation of 75 adults across three groups (adult, elderly, obese; 25 each) receiving procedural moderate-to-deep sedation.
- Propofol target-controlled infusion guided by the Eleveld pharmacokinetic-pharmacodynamic model; no comparator group is described.
- Effect-site targets were generally 2-3 μg/ml in adults and nearer 2 μg/ml in elderly and obese patients, with slight drops in respiratory rate and SpO2 as predicted effect rose.
- The authors conclude the model can achieve moderate-to-deep sedation while keeping respiratory and haemodynamic parameters adequate, allowing safe completion of procedures.
- Double-blind randomised controlled trial of 304 patients undergoing elective hepatectomy, 48% of whom had open surgery.
- Patients received lidocaine with low-dose esketamine or placebo from induction to end of surgery, and the active drugs were infused for 72 hours afterward.
- Movement-evoked pain at 24 hours was lower with lidocaine-esketamine (median 3 vs 4, p < 0.001), with moderate-to-severe pain in 34% vs 56% (p < 0.001).
- Sufentanil consumption fell and quality of recovery scores were higher over the first 72 hours, but the authors describe these changes as clinically modest.
- Resting-state fMRI was performed on 21 healthy volunteers across four states: awake, mild sedation, deep propofol sedation, and postsedation recovery.
- The study compared white matter functional connectivity, both white-to-gray and white-to-white, across these states, with white matter-mediated network global efficiency also analyzed.
- White-to-gray and white-to-white connectivity significantly decreased during deep sedation versus awake (P < .05), with several tracts differing across states (P < .01).
- Global efficiency of the whole-brain network and several large-scale networks fell during deep sedation and returned to awake levels after recovery; authors suggest a possible biomarker role.
- Prospective study of 30 adults under general anesthesia with propofol and remifentanil target-controlled infusion, monitored concurrently with ANI and NOL.
- The two nociception monitors were compared by sorting readings into insufficient, adequate, or excessive analgesia using manufacturer thresholds.
- Across more than 38 hours of paired recordings, the monitors agreed 43.7% of the time, with 1-category and 2-category disagreements in 37.1% and 8.7% of recordings.
- Excessive analgesia was recorded for 37.6% (ANI) and 38.1% (NOL) of surgical time, and the authors suggest a multimodal monitoring strategy may help.
- Observational EEG analysis of 155 adults aged 18-90 yr receiving propofol (n=60) or sevoflurane (n=95) during stable maintenance.
- Spectral power and coherence were modelled against age by linear regression and compared between young (18-38 yr) and elderly (70-90 yr) patients.
- Power across all frequency bands decreased with age for both drugs, with elderly EEG oscillations about 2- to 3-fold smaller in amplitude than in young adults.
- In older patients, alpha power fell more than slow power, alpha coherence and peak frequency were lower, and burst suppression was more likely.
- Animal study of fetal (gestational day 120) and postnatal day 6 rhesus macaques, with 4 fetuses and 4 neonates exposed to propofol and 4 fetuses and 5 neonates as unexposed controls.
- Animals received 5 hours of propofol anaesthesia or no anaesthesia, and brains were examined 3 hours later for apoptosis of neurones and glia.
- Propofol increased neuronal and oligodendrocyte apoptosis at both ages, with oligodendrocyte losses roughly equal to neuronal losses, though the abstract reports no effect sizes or p values.
- Affected regions differed by age: subcortical and caudal regions in fetuses, and a laminar neocortical pattern in neonates. The authors suggest oligodendrocytes become vulnerable as myelination begins, and the injury was less extensive than after isoflurane.
- Phase II, randomized, double-blind, placebo-controlled, four-period crossover multicenter trial in patients with at least moderate painful HIV-associated polyneuropathy, with 15 enrolled across eight sites.
- Compared duloxetine, methadone, their combination, and placebo, with the primary outcome being mean pain intensity recorded in a daily pain diary.
- No statistically significant change in mean pain intensity versus placebo was found, and only eight patients completed the trial amid frequent adverse events and discontinuations.
- The authors attribute the limited efficacy evaluation to recruitment and retention problems and emphasize the lessons learned for future trials.
- In vitro study using human airway smooth muscle cells, testing caveolar fractions for propofol and calcium responses to histamine with and without propofol.
- Compared propofol at 10 and 30 µM against an intralipid control, with caveolin-1 knockdown by siRNA and pharmacological blockade of calcium stores.
- Propofol was detected in caveolar fractions and reduced histamine-induced peak intracellular calcium by about 40%, with the effect absent in caveolin-1 siRNA-transfected cells.
- Propofol also reduced store-operated calcium entry and decreased caveolin-1 expression, and the authors propose caveolar disruption as a mechanism for propofol-induced bronchodilatation.
- Prospective population pharmacokinetic study of 36 infants aged 1 to 24 months after open heart surgery, all requiring postoperative mechanical ventilation.
- Infants were sequentially assigned to one of three loading dose and continuous infusion regimens (0.35-0.25, 0.7-0.5, or 1-0.75 mcg/kg and mcg/kg/h), with plasma concentrations measured by LC-MS/MS-type assay and modeled with a 2-compartment model.
- Estimated clearance was 28.1 mL/min/kg^0.75 and central volume of distribution 1.2 L/kg; clearance rose with weight, age, and single-ventricle physiology, while longer bypass time showed a trend toward lower clearance.
- The authors conclude that weight-dependent clearance supports weight-based dosing, and that the tested loading and infusion doses were well tolerated in this population.